
Artivion (AORT) Stock Forecast & Price Target
Artivion (AORT) Analyst Ratings
Bulls say
Artivion Inc. has demonstrated strong financial performance, evidenced by a 320 basis point increase in adjusted EBITDA margin year-over-year and a 29% growth in adjusted EBITDA to $22.7 million, aligning closely with estimates. The company reported a significant increase in sales, with Preservation Services generating $25.7 million (up 5%) and product sales reaching $87.7 million (up 19%) in the third quarter of 2025. Additionally, Artivion's gross margin improved to 65.6%, exceeding estimates and reflecting a favorable product mix, reinforcing a positive outlook driven by robust revenue growth and margin enhancement.
Bears say
Artivion Inc faces several risks that contribute to a negative outlook, including potential delays in clinical trials and new product approvals, which could hinder future revenue growth. The company’s guidance suggests a concerning trend, with expected revenue growth slowing into the mid- to high-single digits, driven by disappointing new product launches and lackluster international expansion. Furthermore, financial performance has demonstrated inconsistencies, such as the Preservation Services segment missing revenue estimates, highlighting underlying weaknesses in the company's operational efficiency and market demand.
This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.
Artivion (AORT) Analyst Forecast & Price Prediction
Start investing in Artivion (AORT)
Order type
Buy in
Order amount
Est. shares
0 shares